- Home /
- Live Rates /
- UTHR

Last Updated: Jun 03, 2026 03:26:12 PM (GMT)
UTHR: Current live price is 545.545, which shows a percentage change of +1.09% from the previous price.
Support and Resistance Levels Current support levels are 539.66, 539.66, 539.66, with resistance levels of 539.66, 539.66, 539.66. The pivot point is 539.66.
Indicators Current RSI is 33.94, indicating a downtrend in the history. The ATR is at 0.58107, with a significant downtrend also in its history. Current ADX stands at 50.18276, suggesting a strong trend. The current 50-day SMA is 543.0145, while the 200-day EMA is 551.04625. The Parabolic SAR shows a current value of 547.96382.
Market Sentiment The price is below the pivot point (539.66) and indicators show bearish trends overall, suggesting further market decline.
UTHR Signals & Technical Analysis
Market Sentiment
Trend Indicators
Oscillators
Moving Averages
Pivot
About (UTHR) United Therapeutics Corporation
Company Background
United Therapeutics Corporation, traded under the symbol UTHR on the NASDAQ exchange, is a leading biotechnology company based in the United States. Founded in 1996 by Dr. Martine Rothblatt, United Therapeutics is committed to the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company focuses primarily on the treatment of pulmonary arterial hypertension (PAH) and has pioneered several therapies that significantly improve patients' quality of life.
Market Position
United Therapeutics holds a robust position in the biotechnology sector, particularly in the field of pulmonary medicine. The company's diverse portfolio includes several FDA-approved products such as Remodulin, Tyvaso, and Orenitram, which are designed to treat PAH. With a strong commitment to research and development, United Therapeutics actively invests in new therapies and technologies, including an innovative organ transplantation program that aims to revolutionize the field with xenotransplantation solutions. This proactive approach not only strengthens their product pipeline but also enhances their competitive edge in a rapidly evolving market.
Key Financial Highlights
As of the latest fiscal reports, United Therapeutics has demonstrated impressive financial performance, with significant revenue growth driven by increased sales of its specialty pharmaceuticals. The company's disciplined cost management and strategic investments in R&D have resulted in consistent profitability, enabling it to reinvest in innovative projects. With a robust cash position, United Therapeutics is well-equipped to navigate the competitive landscape and pursue future expansion opportunities. Additionally, the growing prevalence of PAH and the increasing demand for effective treatments position United Therapeutics for sustained growth and market leadership in the biopharmaceutical industry.
Conclusion
In summary, United Therapeutics Corporation (NASDAQ: UTHR) stands out as a key player in the biotechnology sector, dedicated to improving patient outcomes through innovative therapies. With a strong financial foundation and a commitment to groundbreaking research, United Therapeutics is poised for continued success as it addresses critical healthcare challenges and advances the field of pulmonary medicine.
How to Buy or Trade United Therapeutics Corporation Stock (UTHR) with AvaTrade
Trading or investing in United Therapeutics Corporation stock through AvaTrade starts with opening a verified trading account. After registration, complete the KYC verification process by submitting your ID and proof of address, then fund your account using a supported payment method such as bank transfer, debit card, or e-wallet. Once your funds reflect, log into the AvaTrade platform or mobile app and search for the ticker symbol UTHR, which represents United Therapeutics Corporation. Before placing a trade, review the live United Therapeutics Corporation share price, market trend, spread, leverage options, and recent market news that could impact the stock price.
The next step is deciding whether you want to buy or sell United Therapeutics Corporation stock. Traders expecting the price to rise typically open a Buy position, while traders expecting weakness in the sector may open a Sell position using CFDs. Enter your preferred trade size, then apply risk management tools such as a stop-loss to limit downside exposure and a take-profit order to secure profits automatically. After confirming the trade, monitor key drivers including United Therapeutics Corporation earnings reports, product or service announcements, business segment performance, revenue growth, and overall stock market sentiment. Many traders also use technical indicators such as moving averages, RSI, and support/resistance levels available on the AvaTrade platform to improve timing and trading decisions.
Related Stocks
Indicator Alert
Warning: Several indicator values are missing for this timeframe. Please choose another timeframe to continue.
Sidebar rates
- <% signal.pair %>
<% signal.analyst %>
